Key Lipoprotein Receptor Targeted Echinacoside-Liposomes Effective Against Parkinson’s Disease in Mice Model
International Journal of Nanomedicine · 2024-08 · Volume 19 · 8463-8483
DOI: 10.2147/ijn.s468942 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2024-08. Verfasst von Zemin Ou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Liposomes, Blood-Brain Barrier, Neuroprotective Agents, Disease Models, Animal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Introduction
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra. The precise molecular mechanisms underlying neuronal loss in PD remain unknown, and there are currently no effective treatments for PD-associated neurodegeneration. Echinacoside (ECH) is known for its neuroprotective effects, which include scavenging cellular reactive oxygen species and promoting mitochondrial fusion. However, the blood-brain barrier (BBB) limits the bioavailability of ECH in the brain, posing a significant challenge to its use in PD treatment.
Methods
We synthesized and characterized PEGylated ECH liposomes (ECH@Lip) and peptide angiopep-2 (ANG) modified liposomes (ECH@ANG-Lip). The density of ANG in ANG-Lip was optimized using bEnd.3 cells. The brain-targeting ability of the liposomes was assessed in vitro using a transwell BBB model and in vivo using an imaging system and LC-MS. We evaluated the enhanced neuroprotective properties of this formulation in a the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model.
Results
The ECH@ANG-Lip demonstrated significantly higher whole-brain uptake compared to ECH@Lip and free ECH. Furthermore, ECH@ANG-Lip was more effective in mitigating MPTP-induced behavioral impairment, oxidative stress, dopamine depletion, and dopaminergic neuron death than both ECH@Lip and free ECH.
Conclusion
The formulation used in our study significantly enhanced the neuroprotective efficacy of ECH in the MPTP-induced PD model. Thus, ECH@ANG-Lip shows considerable potential for improving the bioavailability of ECH and providing neuroprotective effects in the brain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
ORCID-Profile: Zemin Ou, Jinyu Wang
Zitieren
APA
Ou, Z., You, Y., Yi, H., Liu, X., Tong, Y., Liu, D., & Wang, J. (2024). Key Lipoprotein Receptor Targeted Echinacoside-Liposomes Effective Against Parkinson’s Disease in Mice Model. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s468942
Vancouver
Ou Z, You Y, Yi H, Liu X, Tong Y, Liu D, et al. Key Lipoprotein Receptor Targeted Echinacoside-Liposomes Effective Against Parkinson’s Disease in Mice Model. International Journal of Nanomedicine. 2024. doi:10.2147/ijn.s468942
BibTeX
@article{Ou2024,
author = {Ou, Zemin and You, Yun and Yi, Hong and Liu, Xiaoqian and Tong, Yan and Liu, Dewen and Wang, Jinyu},
title = {Key Lipoprotein Receptor Targeted Echinacoside-Liposomes Effective Against Parkinson’s Disease in Mice Model},
journal = {International Journal of Nanomedicine},
year = {2024},
doi = {10.2147/ijn.s468942}
}
EUVIMED